Shillong: The Meghalaya Medical Drugs and Services Limited is facing intense scrutiny over persistent failures in its drug quality control processes. Frequent recalls of essential medications distributed to state health centers have compromised patient safety and placed doctors in a difficult position regarding their professional liability.
Health Department officials report that recall notices often reach hospitals only after patients have already consumed the substandard medication. These systemic lapses undermine the state's recent progress in healthcare and threaten to erode public trust in government medical services.
The most recent incident involves the recall of Iron and Folic Acid pink tablets provided for children under the National Health Mission. In a May 19 directive, Managing Director Ramakrishna Chitturi ordered the immediate cessation of distribution for six specific batches, instructing pharmacists to quarantine and label the stock as unfit for use.
This follows a series of similar incidents spanning the last two years. Previous recalls include IFA Blue tablets that disintegrated in their packaging, epilepsy medication Sodium Valproate, Omeprazole capsules, and batches of Lorazepam. Despite repeated warnings from medical staff about the recurring nature of these quality issues, little effective corrective action has been taken by the supply organization.
Doctors remain worried about the potential for adverse reactions in patients and the legal risks they face when prescribing unreliable medication. Health authorities are now calling for a complete overhaul of procurement and quality assurance standards to prevent future health crises.
Comments